Table 4 Adverse effects after the start of MMI
n | Skin rash | Liver dysfunction | Transient neutropenia | Arthralgia/myalgia | Patients with adverse effects | Pa | ||
|---|---|---|---|---|---|---|---|---|
Group A (mild group, lower dose) | 78 | 2 (2.56%) | 6 (7.69%) | 3 (3.85%) | 2 (2.56%) | 10 (12.82%) | P < 0.01 | |
Group B (moderate group, higher dose) | 37 | 0 | 3 (8.11%) | 1 (2.70%) | 1 (2.70%) | 11 (13.51%) | P < 0.01 | |
Group C (severe group, higher dose) | 24 | 3 (12.50%) | 2 (8.33%) | 1 (4.17%) | 0 | 12 (16.67%) | P < 0.01 | |
Group D (severe group, much higher dose) | 22 | 2 (9.09%) | 5 (22.73%) | 3 (13.64%) | 2 (9.09%) | 13 (40.91%) | Referent |